Group 1 - The core viewpoint of the news is that Xianju Pharmaceutical's subsidiary, Taizhou Xianju Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, allowing it to enjoy a 15% corporate income tax rate for three consecutive years from 2025 to 2027 [1] Group 2 - The company's project, "High-end Formulation Internationalization Construction Project," has been delayed from its original completion date of the end of 2025 to December 31, 2026. As of October 31, 2025, the project has invested 636 million yuan, achieving a progress rate of 90.79%. The delay is primarily due to the incomplete approval processes for certain products [2]

Group 1 - The company Xianju Pharmaceutical has approximately 50,000 shareholders as of recent updates [2]

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

Core Viewpoint - Xianju Pharmaceutical's wholly-owned subsidiary, Taizhou Xianju Pharmaceutical Co., Ltd., has received the "High-tech Enterprise Certificate" from multiple governmental bodies, marking the renewal of its previous certification [1]. Group 1 - The certificate was issued by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1]. - This renewal follows the expiration of the previous high-tech enterprise certificate [1].

证券代码：002332 证券简称：仙琚制药 公告编号：2026-004 浙江仙琚制药股份有限公司 关于全资子公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司的全资子公司台州仙琚药业有限公司（以下简称"台 州仙琚药业"）于近日收到由浙江省经济和信息化厅、浙江省财政厅、国家税务总局 浙江省税务局联合颁发的《高新技术企业证书》，具体情况如下： 企业名称：台州仙琚药业有限公司 发证日期：2025年12月19日 有效期：三年 本次系台州仙琚药业原高新技术企业证书有效期满后的重新认定，根据《中华人 民共和国企业所得税法》的规定，台州仙琚药业通过高新技术企业重新认定后将连续 三年（即2025年、2026年、2027年）按15%的税率缴纳企业所得税。 台州仙琚药业2025年度已根据相关规定按照15%的企业所得税税率进行财务核算， 上述税收优惠政策不会影响公司2025年度的经营业绩。 特此公告。 浙江仙琚制药股份有限公司 董事会 2026年1月30日 证书编号：GR202533003759 ...

Group 1 - The core viewpoint of the article is that Xianju Pharmaceutical (002332) has engaged in preliminary commercialization preparations for the drug Ageng Glucosamine Sodium Injection, but the financial impact on current operations is expected to be minor due to uncertainties in approval and market access [1][1][1] Group 2 - The company has signed various agreements related to the product, but the specific financial amounts have not been disclosed, citing potential commercial confidentiality [1][1] - The product is currently under review, and there are uncertainties regarding its approval and the timeline for market entry, as well as negotiations with health insurance [1][1][1]

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has signed a tripartite agreement with Hangzhou Aomei Pharmaceutical Co., Ltd. and Aspen (Guang Dong) Pharmaceutical Co., Ltd. for the exclusive marketing of the drug Agerglucoside Sodium Injection in mainland China, indicating a strategic move towards commercialization of the product [1][2][12]. Group 1: Agreement Details - The tripartite agreement allows Aspen to act as the exclusive marketing service provider for Agerglucoside Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [2][8]. - The commercialization milestone sharing agreement stipulates a 50% split of milestone payments and net sales revenue between Xianju Pharmaceutical and Aomei Pharmaceutical after deducting relevant costs [2][10]. - Additional agreements include a raw material supply agreement and a contract for commissioned production of Agerglucoside Sodium Injection, ensuring a stable supply and quality assurance for the product [3][10]. Group 2: Company Background - Hangzhou Aomei Pharmaceutical Co., Ltd. was established on October 25, 2000, with a registered capital of 69.825291 million RMB, focusing on medical research, chemical product sales, and drug production [4][5]. - Aspen (Guang Dong) Pharmaceutical Co., Ltd. was founded on January 31, 1997, with a registered capital of 57.6 million USD, specializing in the wholesale and production of various pharmaceutical products [5][6]. Group 3: Impact on Company - The signing of these agreements is a preparatory step for the future commercialization of Agerglucoside Sodium Injection, leveraging Aspen's extensive market experience in the anesthesia field to enhance product promotion and sales [12]. - The agreements clarify the revenue distribution and supply assurance mechanisms for the product post-approval, which is beneficial for the product's market entry and aligns with the interests of the company and its shareholders [12][13].

Core Viewpoint - Xianju Pharmaceutical has established strategic partnerships for the development and commercialization of the drug Aomikson Sodium (also known as Ageng Glucose Sodium Injection) with Hangzhou Aomei Pharmaceutical and Aishijian (Guangdong) Pharmaceutical [1][2] Group 1: Agreements and Collaborations - On December 17, 2015, Xianju Pharmaceutical signed a development cooperation agreement for Aomikson Sodium with Hangzhou Aomei [1] - A supplementary agreement was signed on April 16, 2021, to further the development of Aomikson Sodium [1] - A strategic cooperation framework agreement was signed on January 12, 2023, to outline the collaboration on Aomikson Sodium [1] Group 2: Recent Developments - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian signed a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Aomikson Sodium in mainland China [2] - The commercialization milestone sharing ratio for Aomikson Sodium is set at 50% for both Xianju Pharmaceutical and Hangzhou Aomei [2] - A procurement supply agreement and a supplementary agreement for contract manufacturing of Aomikson Sodium were also signed on January 16, 2026 [2]

Core Viewpoint - Xianju Pharmaceutical has entered into a tripartite agreement with Hangzhou Aomei and Aishijian for the exclusive marketing of Ageng Glucosamine Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The agreement designates Aishijian as the exclusive marketing service provider for Ageng Glucosamine Sodium Injection in mainland China [1] - Xianju Pharmaceutical and Hangzhou Aomei have established a milestone revenue-sharing agreement, with both parties sharing 50% of the commercialization milestone revenue [1] - The net revenue from commercialization sales in mainland China will also be shared equally, with both companies receiving 50% after deducting relevant expenses [1] Group 2 - Xianju Pharmaceutical and Hangzhou Aomei have signed a procurement supply agreement for the raw materials of Ageng Glucosamine Sodium and a supplementary agreement for the commissioned production of the injection [1] - Ageng Glucosamine Sodium Injection is classified as a Class 1 new drug and is a targeted muscle relaxant [1]

Core Viewpoint - The collaboration between Xianju Pharmaceutical and Hangzhou Aomei Pharmaceutical focuses on the development, production, and commercialization of the drug Aomeikongsu Sodium (also known as Ageng Glucose Sodium Injection) [1][2] Group 1: Agreements and Collaborations - Xianju Pharmaceutical signed multiple agreements with Hangzhou Aomei, including the initial development cooperation agreement in December 2015, a supplementary agreement in April 2021, and a strategic cooperation framework agreement in January 2023 [1] - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian (Guangdong) Pharmaceutical Co., Ltd. entered into a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Ageng Glucose Sodium Injection in mainland China [2] - The commercialization milestone sharing agreement and sales revenue sharing agreement stipulate that both Xianju Pharmaceutical and Hangzhou Aomei will share 50% of the commercialization milestones and net sales revenue after deducting relevant expenses [2] Group 2: Product Naming and Regulatory Aspects - The Chinese common name for Aomeikongsu Sodium and its injection form is officially recognized as Ageng Glucose Sodium and Ageng Glucose Sodium Injection, respectively [1] - The agreements outline specific terms regarding the procurement of raw materials and contract manufacturing for Ageng Glucose Sodium Injection [2]